Boehringer Ingelheim's Carine Boustany Appointed to BIO Board

News provided by

Boehringer Ingelheim Pharmaceuticals, Inc.

Nov 16, 2021, 08:00 ET

RIDGEFIELD, Conn., Nov. 16, 2021 /PRNewswire/ -- Boehringer Ingelheim announced today that Carine Boustany, Ph.D., Global Head, Development Science + Head, Development Site U.S., has been appointed to the BIO Board of Directors. In this role, she will also serve on the Health Section Governing Board and Access and Value Committee.

BIO, as the world's largest biotechnology advocacy association, represents member companies, academic and research institutions, as well as other related organizations across the United States and over 30 countries worldwide. It focuses on advancing the biotechnology industry through the pursuit of partnerships and enriched connectivity, while also spearheading the BIO International Convention, the world's largest meeting within the biotechnology industry.

"BIO plays a pivotal role in advancing innovation in biotechnology on a global scale and I am honored and excited to represent Boehringer Ingelheim and help drive our shared mission of progressing science toward delivering innovative medicines for the patients," said Carine Boustany. "As a member of BIO's board of directors, I will continue to champion scientific innovation that puts the patient first."

Boustany joined Boehringer Ingelheim in 2011 and took on her current role in January 2021. Prior to this, she was a part of Boehringer Ingelheim's Discovery Research team and led the Department of Cardio-Metabolic Diseases Research in Ridgefield.

"We are excited to welcome Carine Boustany to the BIO Board of Directors. Her expertise and passion for bringing life changing therapies to patients will play a critical role in our ability to advocate for the type of policy and regulatory environment that drives innovation and better health outcomes for people around the world," said Michelle McMurry-Heath, M.D., President & CEO of BIO.

About Boehringer Ingelheim

Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.

As a world-leading, research-driven pharmaceutical company, with around 52,000 employees, we create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2020, Boehringer Ingelheim achieved net sales of around 22.33 billion USD (19.57 billion EUR). Our significant investment of over 4.2 billion USD (3.7 billion EUR) in 2020 (18.9% of net sales) in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.

We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation and is part of the Boehringer Ingelheim group of companies. In addition, there are Boehringer Ingelheim Animal Health in Duluth, GA and Boehringer Ingelheim Fremont, Inc. in Fremont, CA.

Boehringer Ingelheim is committed to improving lives and strengthening our communities. Please visit www.boehringer-ingelheim.us/csr to learn more about Corporate Social Responsibility initiatives.

For more information, please visit www.boehringer-ingelheim.us, or follow us on Twitter @BoehringerUS.

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.